FOSTER CITY, California, United States & MUNICH, Germany, April 7, 2026
Gilead Sciences, Inc. announced a definitive agreement to acquire Tubulis GmbH, a clinical-stage biotechnology company specializing in antibody-drug conjugates (ADCs), in a deal valued at up to $5 billion, including upfront and milestone payments. The acquisition significantly strengthens Gilead’s oncology pipeline and next-generation targeted therapy capabilities, positioning the company at the forefront of precision cancer treatment innovation.
Acquisition Strengthens ADC Pipeline and Innovation Platform
The transaction will add Tubulis’ advanced ADC platform and clinical-stage assets to Gilead’s portfolio, including TUB-040, a NaPi2b-targeting ADC currently in Phase 1b/2 clinical trials for platinum-resistant ovarian cancer and non-small cell lung cancer, as well as TUB-030, a 5T4-targeted ADC showing promising early clinical data across multiple tumor types.
ADCs represent a rapidly growing class of targeted cancer therapies that combine the precision of monoclonal antibodies with potent cytotoxic payloads, enabling selective delivery of drugs directly to tumor cells while minimizing systemic toxicity. Tubulis’ proprietary Tubutecan linker-payload technology and next-generation conjugation platforms are designed to enhance stability, improve tumor targeting, and increase therapeutic efficacy, making them highly valuable additions to Gilead’s oncology strategy.
This acquisition builds on an existing collaboration between the two companies and reflects Gilead’s long-term commitment to expanding its capabilities in advanced biologics and targeted cancer therapies.
Advertisement
Strategic Investment to Address High Unmet Medical Needs
The deal aligns with Gilead’s broader mission to address critical gaps in cancer care, particularly in hard-to-treat solid tumors where treatment options remain limited. The addition of Tubulis’ pipeline enhances Gilead’s ability to develop innovative therapies for high unmet medical need indications, including ovarian cancer and lung cancer.
Following the acquisition, Tubulis will operate as a dedicated ADC research unit within Gilead, with its Munich site serving as a center of excellence for ADC innovation, integrating discovery, manufacturing, and clinical development capabilities.
The transaction also reflects a broader industry trend of large pharmaceutical companies acquiring innovative biotech platforms to accelerate drug discovery, clinical development, and commercialization timelines, particularly in the competitive oncology space.
Financial Structure and Future Growth Opportunities
Under the terms of the agreement, Gilead will pay $3.15 billion upfront, with an additional $1.85 billion in contingent milestone payments, subject to regulatory approvals and other customary closing conditions. The transaction is expected to close in the second quarter of 2026 and will be financed through a combination of cash reserves and debt instruments.
This strategic investment further strengthens Gilead’s position as a leader in oncology innovation, complementing its existing portfolio of cell therapies, small molecules, and biologics. By integrating Tubulis’ cutting-edge ADC technologies, Gilead aims to accelerate the development of next-generation cancer treatments with improved efficacy and safety profiles.
The acquisition of Tubulis represents a significant milestone in Gilead’s strategy to expand its oncology pipeline and advanced therapeutic platforms, reinforcing the importance of innovation, clinical development, and strategic partnerships in the biopharmaceutical industry. With a strong focus on targeted therapies and precision medicine, this deal positions Gilead to deliver transformative cancer treatments and address some of the most pressing challenges in oncology.
As the demand for highly effective and targeted cancer therapies continues to grow, investments in technologies such as ADCs are expected to play a critical role in shaping the future of biopharma innovation and patient care.
Source: Gilead Sciences, Tubulis press release
